Review
Medicine, Research & Experimental
Sajad Najafi, Jamal Majidpoor, Keywan Mortezaee
Summary: Immunotherapy and oncolytic virotherapy have revolutionized cancer treatment. The combination of monoclonal antibodies targeting PD-1/PD-L1 with oncolytic Ads has shown promising potential in improving clinical responses to immune checkpoint inhibitors.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Chemistry, Multidisciplinary
Seong Dong Jeong, Bo-Kyeong Jung, Hyo Min Ahn, DaeYong Lee, JongHoon Ha, Ilkoo Noh, Chae-Ok Yun, Yeu-Chun Kim
Summary: The study demonstrates the potential of fluorinated mitochondria-disrupting helical polypeptides (MDHPs) in inducing immunogenic cell death (ICD) and activating antitumor immune responses. By destabilizing the mitochondrial outer membrane and triggering excessive ROS production and apoptosis, the helical polypeptide leads to ER stress-mediated ICD. The combination therapy of fluorinated MDHP and anti-PD-L1 antibodies shows promising results in regression of tumor growth and prevention of metastasis, suggesting a synergistic effect with immune checkpoint blockade therapy.
Article
Medicine, Research & Experimental
Yujeong Moon, Man Kyu Shim, Jiwoong Choi, Suah Yang, Jinseong Kim, Wan Su Yun, Hanhee Cho, Jung Yeon Park, Yongju Kim, Joon-Kyung Seong, Kwangmeyung Kim
Summary: In this study, the researchers propose a new strategy to enhance cancer immunotherapy by using anti-PD-L1 peptide-conjugated prodrug nanoparticles (PD-NPs). The PD-NPs are taken up by cancer cells and release the drug, resulting in the disruption of immune-suppressing pathways and the enhancement of T lymphocyte immune responses. The results show that PD-NPs accumulate in tumor tissues and recruit a large amount of immune cells, leading to effective antitumor effects. This strategy has the potential to overcome the toxicity and low response rate issues in current cancer immunotherapy.
Article
Oncology
Tianyu Tang, Xing Huang, Gang Zhang, Minghao Lu, Zhengtao Hong, Meng Wang, Junming Huang, Xiao Zhi, Tingbo Liang
Summary: This study demonstrates that LTX-315 can enhance lymphocyte infiltration and induce an antitumor immune response by inhibiting PD-L1 expression in pancreatic tumors. ATP11B is identified as a potential target of LTX-315 and a critical regulator in maintaining PD-L1 expression.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Materials Science, Biomaterials
Seong Dong Jeong, Bo-Kyeong Jung, DaeYong Lee, JongHoon Ha, Han-Gyu Chang, Jeongmin Lee, Susam Lee, Chae-Ok Yun, Yeu-Chun Kim
Summary: This study reports a tannic acid (TA)-Fe3+-coated doxorubicin (DOX)-encapsulated micelle for inducing immunogenic cell death (ICD) through apoptosis/ferroptosis pathways. The in vivo results show that the combination treatment considerably inhibits tumor growth and improves antitumor immunity.
ACS BIOMATERIALS SCIENCE & ENGINEERING
(2022)
Article
Materials Science, Biomaterials
Xiaoyan Sun, Jiulong Zhang, Jingya Xiu, Xiufeng Zhao, Chunrong Yang, Dan Li, Kexin Li, Haiyang Hu, Mingxi Qiao, Dawei Chen, Xiuli Zhao
Summary: A phenolic-based tumor-permeated nano-framework (EGPt-NF) was developed to improve tumor immunogenicity and enhance the efficacy of cancer immunotherapy. This approach induces immunogenic cell death, downregulates PD-L1 expression, and relieves tumor hypoxia, resulting in an increased antitumor immune response and inhibition of primary tumor and metastasis.
BIOMATERIALS SCIENCE
(2022)
Article
Oncology
Sen Yan, Han Zeng, Kaifeng Jin, Fei Shao, Zhaopei Liu, Yuan Chang, Yiwei Wang, Yu Zhu, Zewei Wang, Le Xu, Jiejie Xu
Summary: The expression of NKG2A and PD-L1 together can be used as a combinatorial biomarker to predict the therapeutic response to immune checkpoint blockade in patients with muscle-invasive bladder cancer.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Christine M. Minnar, Paul L. Chariou, Lucas A. Horn, Kristin C. Hicks, Claudia Palena, Jeffrey Schlom, Sofia R. Gameiro
Summary: This study demonstrates that the combination of entinostat and NHS-IL12 therapy can effectively inhibit tumor growth and prolong survival in alpha PD-1/alpha PD-L1 resistant tumors with deficiencies in MHC-I, APM, and IFN-γ signaling. The combination therapy activates cytotoxic CD8(+) T cells and modulates the tumor microenvironment by promoting M1-like macrophages and activated antigen-presenting cells while decreasing M2-like macrophages and regulatory T cells. Additionally, the therapy increases levels of IFN-γ, IL-12, CXCL9, and CXCL13 in the tumor microenvironment and promotes upregulation of MHC-I and APM.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Yukiko Yamaguchi, Jackson Gibson, Kevin Ou, Lupita S. Lopez, Rachel H. Ng, Neena Leggett, Vanessa D. Jonsson, Jelani C. Zarif, Peter P. Lee, Xiuli Wang, Catalina Martinez, Tanya B. Dorff, Stephen J. Forman, Saul J. Priceman
Summary: This study reveals an alternative mechanism by which the combination of CAR T cells and immune checkpoint blockade modulates the immune landscape of solid tumors to enhance therapeutic efficacy of CAR T cells.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Immunology
Yuedi Zhang, Qiulin Cui, Manman Xu, Duo Liu, Shuzhong Yao, Ming Chen
Summary: Immunotherapies have revolutionized cancer treatment, but recurrent ovarian cancer remains difficult to treat. Recurrent ovarian cancer is a cold tumor with limited response to immunotherapy. However, combining immunotherapy with other treatments may improve outcomes.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Chia-Jung Li, Li-Te Lin, Ming-Feng Hou, Pei-Yi Chu
Summary: Significant progress has been made in understanding the role of PD-L1 in breast cancer, especially in TNBC. Early clinical trials of PD-L1/PD-1 inhibitors have shown efficacy in refractory metastatic breast cancer patients, particularly in TNBC. Mechanisms and factors influencing the immunoediting process have been summarized and analyzed in detail.
Article
Immunology
Zhang-Wei Hu, Wei Sun, Yi-Hui Wen, Ren-Qiang Ma, Lin Chen, Wen-Qing Chen, Wen-Bin Lei, Wei-Ping Wen
Summary: CD69 and SBK1 are potential biomarkers to predict response to cancer immunotherapy, guiding treatment decisions for precision therapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Yvette Robbins, Jay Friedman, Paul E. Clavijo, Cem Sievers, Ke Bai, Renee N. Donahue, Jeffrey Schlom, Andrew Sinkoe, Christian S. Hinrichs, Clint Allen, Houssein Abdul Sater, James L. Gulley, Scott Norberg
Summary: In this study, dual PD-L1/TGF-b inhibition did not effectively inhibit papilloma growth in RRP patients and even increased the need for clinical interventions in some subjects post-treatment. TGF-b neutralization decreased proliferation within papillomas, indicating that intact TGF-b signaling restrains proliferation. Dual PD-L1/TGF-b inhibition did not enhance anti-HPV immunity within papillomas beyond what was observed with PD-L1 blockade.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Veronica Olivo Pimentel, Damienne Marcus, Alexander M. A. van der Wiel, Natasja G. Lieuwes, Rianne Biemans, Relinde I. Y. Lieverse, Dario Neri, Jan Theys, Ala Yaromina, Ludwig J. Dubois, Philippe Lambin
Summary: This study aimed to trigger curative therapeutic responses in poorly immunogenic tumors by combining L19-IL2 and/or immune checkpoint blockade (ICB) with radiotherapy. The results showed that combining RT, anti-PD-L1, and L19-IL2 cured 38% of LLC tumors, which was dependent on both CD8(+) T and NK cells. Triple combinations were not superior to RT+L19-IL2 in the tumor models tested.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Biotechnology & Applied Microbiology
Cao Dai Phung, Bao Loc Nguyen, Jee-Heon Jeong, Jae-Hoon Chang, Sung Giu Jin, Han-Gon Choi, Sae Kwang Ku, Jong Oh Kim
Summary: This study proposes a nanoparticle-based strategy to activate "cold" tumors and enhance the efficacy of cancer immunotherapy. The developed LTX/siR-NPs can inhibit TGF-beta 1 secretion, induce immunogenic cell death, and increase infiltration of antitumor immune cells. Combined treatment with NKG2A checkpoint inhibitors significantly inhibits tumor growth and prolongs survival in mice.
BIOENGINEERING & TRANSLATIONAL MEDICINE
(2023)
Review
Chemistry, Multidisciplinary
Zhiyuan Shi, Yong Hu, Xin Li
Summary: Controlled drug delivery systems that can respond to mechanical force offer a unique solution for on-demand drug activation and release. Among various mechanical stimuli, ultrasound (US) has advantages in achieving spatiotemporally controlled drug release. Traditional US-triggered drug release relies on heat-induced phase transitions or chemical transformations, while the cutting-edge approach of Sonopharmacology leverages polymer mechanochemistry. The remaining challenges and potential future directions in this field are also discussed.
JOURNAL OF CONTROLLED RELEASE
(2024)
Article
Chemistry, Multidisciplinary
Lijie Zheng, Yuanzheng Chen, Xun Gu, Yingying Li, Hanqing Zhao, Wenjun Shao, Tao Ma, Chuanbin Wu, Qingqing Wang
Summary: In this study, a novel dosage form consisting of dissolving microneedles and an adhesive transdermal patch was developed for the treatment of rheumatoid arthritis. In vitro and in vivo experiments demonstrated that the combination of drugs delivered by this dosage form effectively reduced joint inflammation and damage.
JOURNAL OF CONTROLLED RELEASE
(2024)
Article
Chemistry, Multidisciplinary
Kyungjik Yang, Hwa Seung Han, Seung Hwan An, Kyung Hoon Park, Keonwook Nam, Shinha Hwang, Yuyeon Lee, Sung Yeon Cho, Taehyung Kim, Deokyeong Choe, Sang Won Kim, Wonkyu Yu, Hyunah Lee, Jiyong Park, Sangguan You, Dong- Gyu Jo, Ki Young Choi, Young Hoon Roh, Jae Hyung Park
Summary: This study developed CP-loaded CS microcapsules to enhance the oral bioavailability of CP through controlled gastrointestinal delivery. The optimized microcapsules exhibited desirable physicochemical properties, showed anti-photoaging effects via antioxidant activity, and achieved controlled release in the gastrointestinal tract. This research provides a simple and economical approach for enhancing the oral bioavailability of CP for customized bioactive compound administration.
JOURNAL OF CONTROLLED RELEASE
(2024)
Article
Chemistry, Multidisciplinary
Huiyang Li, Shuo Liu, Wenjin Dai, Bingmei Yao, Yong Zhou, Sujia Si, Hairong Yu, Riguang Zhao, Fang Jin, Liqun Jiang
Summary: Changes in bodily fluid pressures are crucial in diseases like high-altitude pulmonary edema (HAPE). Researchers have developed hydrostatic pressure-sensitive multivesicular liposomes (PSMVLs) that can release drugs in response to pressure changes, with potential applications in HAPE treatment. Animal experiments showed that this system provides better protection for lung tissues and respiratory function, reducing the occurrence of pulmonary edema.
JOURNAL OF CONTROLLED RELEASE
(2024)
Article
Chemistry, Multidisciplinary
Qian Hu, Hongbing Lan, Yinmei Tian, Xiaonan Li, Mengmeng Wang, Jiao Zhang, Yulin Yu, Wei Chen, Li Kong, Yuanyuan Guo, Zhiping Zhang
Summary: Coacervate droplets formed through liquid-liquid phase separation have potential as delivery vesicles for therapeutics. However, their lack of physiological stability and membranes are challenges. In this study, polylysine-polynucleotide complex coacervate droplets with favorable stability were formulated to concentrate molecules and nanoparticles. Phospholipid membranes were further coated on the droplets to create coacervate-based artificial protocells (ArtPC) with membrane-like structures. These biofunctional ArtPC effectively reduced blood uric acid levels and prevented renal injuries.
JOURNAL OF CONTROLLED RELEASE
(2024)
Article
Chemistry, Multidisciplinary
Xiaowei Wang, Hongwei Lu, Fang Luo, Dan Wang, Apeng Wang, Xuelei Wang, Wenkai Feng, Xiaobo Wang, Jiayi Su, Mingliang Liu, Guimin Xia
Summary: Four novel lipid-like GEM diesters were synthesized and encapsulated into liposomes to improve the antitumor efficacy of Gemcitabine. The liposomes loaded with dimyristoyl GEM (LipodmGEM) showed enhanced cellular uptake, improved inhibition of cell migration, and a greatly extended half-life compared to free Gemcitabine. LipodmGEM successfully enriched the drug in the tumor and exhibited excellent anticancer efficacy in vivo with negligible systemic toxicity.
JOURNAL OF CONTROLLED RELEASE
(2024)
Article
Chemistry, Multidisciplinary
Pengyu Li, Jieyi Pan, Yating Dong, Yingying Sun, Yalong Wang, Kang Liao, Yili Chen, Xin Deng, Shihui Yu, Haiyan Hu
Summary: Chronic pulmonary infection caused by Pseudomonas aeruginosa is a serious public health problem with high mortality rates. In this study, infection-microenvironment responsive nanoparticles were developed to eradicate biofilms and inhibit virulence. These nanoparticles showed promising results in treating chronic pulmonary infections.
JOURNAL OF CONTROLLED RELEASE
(2024)
Article
Chemistry, Multidisciplinary
Yajing Sun, Ze Lu, John A. Taylor, Jessie L. S. Au
Summary: A recent development in cancer chemotherapy is the use of cytotoxics to induce tumor-specific immune response through immunogenic cell death (ICD). This study describes a method that utilizes immunostaining and machine-learning to identify cells with ecto-CRT in intact 3-dimensional tissues. The method was successfully applied to study drug-induced ICD in human bladder cancer.
JOURNAL OF CONTROLLED RELEASE
(2024)
Review
Chemistry, Multidisciplinary
Rafat Ali, Shantanu Sen, Rohil Hameed, Aamir Nazir, Sandeep Verma
Summary: This review provides a focused overview of emerging strategies for delivering gasotransmitters in a controlled and sustained manner to reestablish neurophysiological homeostasis.
JOURNAL OF CONTROLLED RELEASE
(2024)
Article
Chemistry, Multidisciplinary
Jing Chen, Xinyi Zhang, Jinshen Zhang, Zhaoxia Wang, Guilan Zhu, Ming Geng, Jinmiao Zhu, Yajun Chen, Wei Wang, Youcui Xu
Summary: In this study, a multifunctional responsive hydrogel system was developed for synergistic reoxygenation and chemo/photothermal therapy. The hydrogel system showed both therapeutic effects against metastatic breast cancer and wound infection, making it a promising strategy for treating and preventing tumor recurrence and associated wound infection.
JOURNAL OF CONTROLLED RELEASE
(2024)
Article
Chemistry, Multidisciplinary
Baoshan Huang, Na Zhang, Xinying Qiu, Rui Zeng, Shuimiao Wang, Mengxia Hua, Qing Li, Kaihui Nan, Sen Lin
Summary: This study revealed that robust ROS can oxidize mitochondrial DNA (ox-mtDNA) and cause its release into the cytosol, resulting in the activation of NLRP3 inflammasome. By using the mitochondria-targeted antioxidant SkQ1 and a novel mitochondria-targeted nanoparticle (SkQ1 NP), it was found that mitochondrial ROS scavenging could in situ inhibit DED-induced mtDNA oxidation and suppress NLRP3-mediated inflammation.
JOURNAL OF CONTROLLED RELEASE
(2024)
Article
Chemistry, Multidisciplinary
Wenqi Liu, Cheng Hu, Linyu Long, Shuyi He, Wen Zhang, Zhicun Wang, Li Yang, Yunbing Wang
Summary: Myocardial infarction is the leading cause of cardiovascular mortality, and current treatment methods have limitations. This study developed a smart carrier that can release different therapeutic substances for different pathological processes, effectively improving cardiac function, promoting cardiac repair, and preventing ventricular remodeling.
JOURNAL OF CONTROLLED RELEASE
(2024)